PEG can increase the apparent relative molecular mass of spherically modified proteins by 5 to 10 times and significantly reduce the glomerular filtration of protein drugs
These efforts have led to the development of various GLP-1 receptor agonists, the most recent being semaglutide and tirzepatide, approved for the treatment of type 2 diabetes in 2018 and 2022, respectively
Suppresses Tumor Growth: Inhibits tumor cell proliferation and induces cell death
By targeting the gut, pancreas, and brain simultaneously, they reduce cravings, stabilize metabolism, and create sustainable results
Many people using tirzepatide notice they feel satisfied faster during meals and think less about food throughout the day
Other factors to consider include: Travel and time zone changes if crossing multiple time zones, the injection day may need to be adjusted temporarily